<DOC>
	<DOCNO>NCT01078311</DOCNO>
	<brief_summary>Sorafenib improve overall survival progression free survival advance hepatocellular carcinoma . Wide interindividual pharmacokinetic variability observe . Data early phase trial solid tumour show trough sorafenib level associate incidence skin rash hypertension . Rash , hypertension high trough level moderately predictive progression free survival.The trough level sorafenib may predictive survival response patient treat sorafenib advanced hepatocellular carcinoma .</brief_summary>
	<brief_title>Drug Monitoring Sorafenib Patients With Advanced Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<criteria>ECOG â‰¤ 2 Histologically cytologically diagnose hepatocellular carcinoma , diagnosis least one crosssectional image characteristic appearance HCC ( i.e . liver lesion arterial enhancement portal venous washout ) Decision treat single agent sorafenib 400mg bid ( dose reduction interruption permit side effect occur treatment ) No prior systemic chemotherapy target therapy ChildPugh liver function class A B At least one untreated target lesion measure one dimension accord RECIST Adequate organ function Prior systemic chemotherapy molecularly target therapy Concurrent active malignancy Concomitant strong CYP3A4 induce inhibitor therapeutic dose ( see section 6.4.1 ) Medical psychiatric condition compromise patient 's ability give inform consent Hypertension control medication ( &gt; 150/100 mmHg despite optimal medical therapy ) History , know brain metastasis ( skull metastasis allow ) , carcinomatous meningitis , leptomenigeal disease Major surgery ( e.g . open abdominal therapy , pelvic , thoracic , orthopaedic neurosurgery ) within 4 week date first dose Localregional treatment ( i.e . percutaneous transarterial procedure ) within 4 week . Restaging CT MRI scan must repeat least 4 week localregional treatment within 3 week date first dose For patient treated Yttrium ( 90Y ) radiotherapy , washout period 2 month require . Evidence severe uncontrolled systemic disease concurrent condition investigator 's opinion make undesirable patient participate study would jeopardize compliance protocol Pregnancy breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>Patients advance hepatocellular cancer</keyword>
</DOC>